vs 9,062 other HR bills in the 116th — cohort avg 39d
Summary
Protect Medical Innovation Act of 201 9 This bill repeals the excise tax on the sale of a medical device by the manufacturer, producer, or importer.
Lobbying filings that explicitly cite this bill (50)
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Cited source text, amounts, lobbyists, and targets
S.692 & H.R.2207 - Protect Medical Innovation Act of 2019
S.503 & H.R.1366 - Responsible Additions & Increases to Sustain Employee Health Benefits Act of 2019
S.684 - Middle Class Health Benefits Tax Repeal Act of 2019
H.R.7149 - To amend the Internal Revenue Code of 1986 to provide special disposition rules for unused benefits in flexible spending arrangements of individuals for calendar year 2020.
Client expense: Not reported · Firm income: $20,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Occupational Safety & Health Administration (OSHA), SENATE, Treasury, Dept of
Cited source text, amounts, lobbyists, and targets
H.R. 3, Lower Drug Costs Now Act of 2019
H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019
H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019
H.R. 448/S. 99, Medicare Drug Price Negotiation Act
H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act
H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019
H.R. 1384, Medicare for All Act of 2019
H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019
H.R. 1425, Patient Protection and Affordable Care Enhancement Act
H.R. 1865, Further Consolidated Appropriations Act, 2020
H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019
H.R. 1985, Family Savings for Kids and Seniors Act
H.R. 2207, Protect Medical Innovation Act of 2019
H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019
H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
H.R. 6201, Families First Coronavirus Response Act
H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act
H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021
S. 12, Health Savings Act of 2019
S. 61, Safe and Affordable Drugs from Canada Act of 2019
S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019
S. 64, Preserve Access to Affordable Generics and Biosimilars Act
S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act
S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package
S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019
S. 344, Hatch-Waxman Integrity Act of 2019
S. 470, Medicare at 50 Act
S. 684, Middle Class Health Benefits Tax Repeal Act of 2019
S. 692, Protect Medical Innovation Act of 2019
S. 1416, Affordable Prescriptions for Patients Act of 2019
S. 1541, Tobacco-Free Youth Act
S. 1895, Lower Health Care Costs Act
S. 2543, Prescription Drug Pricing Reduction Act of 2019
S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act
S. 3200, Chronic Disease Management Act of 2020
S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act
S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act
Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.)
Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019)
Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019)
Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020)
Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, medical malpractice reform, the impact on small business, section 1557 on nondiscrimination, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557;
Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs;
association health plans;
importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations;
balance or surprise billing and related issues;
single-payer health care options;
health reimbursement arrangements and other account-based group health plans;
Health and Human Services international pricing index (IPI) model;
legislation addressing mental health parity;
inclusion of prescription drug pricing on 2019 congressional agenda;
reauthorization of the Patient Centered Outcomes Research Institute (PCORI);
potential premium reduction/reinsurance program to reduce health insurance premiums;
proposals to expand Medicare including Medicare Buy-In and the development of a public option;
Medicare hospital outpatient prospective payment system for CY 2020;
drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates;
potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty;
comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements;
comments on Medicare Program; modernizing and clarifying the physician self-referral regulations;
comments on CMS proposed Medicaid fiscal accountability regulation;
comments on CMS proposed transparency in coverage rule;
comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d);
comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program;
Medicaid fiscal accountability regulation;
comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D;
transparency in coverage;
issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies;
Public Health and Social Services Emergency Fund (PHSSEF);
health insurance coverage during the coronavirus pandemic;
health legislative priorities for the potential Phase 4 coronavirus relief package;
provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements (FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136);
FCCs COVID-19 Telehealth Program;
Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use;
distribution of COVID-19 vaccines;
comments on notice of proposed rulemaking: securing updated and necessary statutory evaluations timely (SUNSET);
reform of the World Health Organization (WHO);
continued U.S. membership in the World Health Organization;
COVID-19 liability issues;
Phase IV COVID-19 relief legislation and civil liability issues affecting the business community
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Cited source text, amounts, lobbyists, and targets
H.R. 2207/S.692 - Protect Medical Innovation Act of 2019
H.R. 1865 - Further Consolidated Appropriations Act, 2020
no specific bill, tariff and trade policies
Client expense: Not reported · Firm income: $60,000
Cited source text, amounts, lobbyists, and targets
H.R. 3, Lower Drug Costs Now Act of 2019
H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019
H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019
H.R. 448/S. 99, Medicare Drug Price Negotiation Act
H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act
H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019
H.R. 1384, Medicare for All Act of 2019
H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019
H.R. 1425, Patient Protection and Affordable Care Enhancement Act
H.R. 1865, Further Consolidated Appropriations Act, 2020
H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019
H.R. 1985, Family Savings for Kids and Seniors Act
H.R. 2207, Protect Medical Innovation Act of 2019
H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019
H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
H.R. 6201, Families First Coronavirus Response Act
H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act
H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021
S. 12, Health Savings Act of 2019
S. 61, Safe and Affordable Drugs from Canada Act of 2019
S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019
S. 64, Preserve Access to Affordable Generics and Biosimilars Act
S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act
S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package
S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019
S. 344, Hatch-Waxman Integrity Act of 2019
S. 470, Medicare at 50 Act
S. 684, Middle Class Health Benefits Tax Repeal Act of 2019
S. 692, Protect Medical Innovation Act of 2019
S. 1416, Affordable Prescriptions for Patients Act of 2019
S. 1541, Tobacco-Free Youth Act
S. 1895, Lower Health Care Costs Act
S. 2543, Prescription Drug Pricing Reduction Act of 2019
S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act
S. 3200, Chronic Disease Management Act of 2020
S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act
Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.)
Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and
payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019)
Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019)
Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020)
Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557;
Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs;
association health plans;
importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations;
balance or surprise billing and related issues;
single-payer health care options;
health reimbursement arrangements and other account-based group health plans;
Health and Human Services international pricing index (IPI) model;
legislation addressing mental health parity;
inclusion of prescription drug pricing on 2019 congressional agenda;
reauthorization of the Patient Centered Outcomes Research Institute; (PCORI);
potential premium reduction/reinsurance program to reduce health insurance premiums;
proposals to expand Medicare including Medicare Buy-In and the development of a public option;
medical hospital outpatient prospective payment system for CY 2020;
drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates;
potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty;
comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements;
comments on Medicare Program; modernizing and clarifying the physician self-referral regulations;
comments on CMS proposed Medicaid fiscal accountability regulation;
comments on CMS proposed transparency in coverage rule;
comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d);
comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program;
Medicaid fiscal accountability regulation;
comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D;
transparency in coverage;
issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies;
Public Health and Social Services Emergency Fund (PHSSEF);
health insurance coverage during the coronavirus pandemic;
health legislative priorities for the potential Phase 4 coronavirus relief package;
provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements
(FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136);
FCCs COVID-19 Telehealth Program;
Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and
Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use;
reform of the World Health Organization (WHO);
continued U.S. membership in the World Health Organization
Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19;
potential legislation dealing with COVID-19 liability issues
Government targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Reserve System, Federal Trade Commission (FTC), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR), White House Office
Client expense: $20,000,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Reclamation, Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Motor Carrier Safety Administration, Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation Security Administration (TSA), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR), White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Cited source text, amounts, lobbyists, and targets
S.692 & H.R.2207 - Protect Medical Innovation Act of 2019
S.503 & H.R.1366 - Responsible Additions & Increases to Sustain Employee Health Benefits Act of 2019
S.684 - Middle Class Health Benefits Tax Repeal Act of 2019
Client expense: Not reported · Firm income: $20,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Occupational Safety & Health Administration (OSHA), SENATE, Treasury, Dept of
Cited source text, amounts, lobbyists, and targets
H.R. 3, Lower Drug Costs Now Act of 2019
H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019
H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019
H.R. 448/S. 99, Medicare Drug Price Negotiation Act
H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act
H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019
H.R. 1384, Medicare for All Act of 2019
H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019
H.R. 1425, Patient Protection and Affordable Care Enhancement Act
H.R. 1865, Further Consolidated Appropriations Act, 2020
H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019
H.R. 1985, Family Savings for Kids and Seniors Act
H.R. 2207, Protect Medical Innovation Act of 2019
H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019
H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
H.R. 6201, Families First Coronavirus Response Act
H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act
H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021
S. 12, Health Savings Act of 2019
S. 61, Safe and Affordable Drugs from Canada Act of 2019
S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019
S. 64, Preserve Access to Affordable Generics and Biosimilars Act
S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act
S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package
S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019
S. 344, Hatch-Waxman Integrity Act of 2019
S. 470, Medicare at 50 Act
S. 684, Middle Class Health Benefits Tax Repeal Act of 2019
S. 692, Protect Medical Innovation Act of 2019
S. 1416, Affordable Prescriptions for Patients Act of 2019
S. 1541, Tobacco-Free Youth Act
S. 1895, Lower Health Care Costs Act
S. 2543, Prescription Drug Pricing Reduction Act of 2019
S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act
S. 3200, Chronic Disease Management Act of 2020
S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act
Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.)
Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and
payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019)
Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019)
Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020)
Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557;
Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs;
association health plans;
importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations;
balance or surprise billing and related issues;
single-payer health care options;
health reimbursement arrangements and other account-based group health plans;
Health and Human Services international pricing index (IPI) model;
legislation addressing mental health parity;
inclusion of prescription drug pricing on 2019 congressional agenda;
reauthorization of the Patient Centered Outcomes Research Institute; (PCORI);
potential premium reduction/reinsurance program to reduce health insurance premiums;
proposals to expand Medicare including Medicare Buy-In and the development of a public option;
medical hospital outpatient prospective payment system for CY 2020;
drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates;
potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty;
comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements;
comments on Medicare Program; modernizing and clarifying the physician self-referral regulations;
comments on CMS proposed Medicaid fiscal accountability regulation;
comments on CMS proposed transparency in coverage rule;
comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d);
comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program;
Medicaid fiscal accountability regulation;
comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D;
transparency in coverage;
issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies;
Public Health and Social Services Emergency Fund (PHSSEF);
health insurance coverage during the coronavirus pandemic;
health legislative priorities for the potential Phase 4 coronavirus relief package;
provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements
(FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136);
FCCs COVID-19 Telehealth Program;
Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and
Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use;
reform of the World Health Organization (WHO);
continued U.S. membership in the World Health Organization
Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19;
potential legislation dealing with COVID-19 liability issues
Client expense: $20,000,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Reclamation, Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Motor Carrier Safety Administration, Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation Security Administration (TSA), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR), White House Office
Cited source text, amounts, lobbyists, and targets
H.R. 3, Lower Drug Costs Now Act of 2019
H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019
H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019
H.R. 448/S. 99, Medicare Drug Price Negotiation Act
H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act
H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019
H.R. 1384, Medicare for All Act of 2019
H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019
H.R. 1425, Patient Protection and Affordable Care Enhancement Act
H.R. 1865, Further Consolidated Appropriations Act, 2020
H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019
H.R. 1985, Family Savings for Kids and Seniors Act
H.R. 2207, Protect Medical Innovation Act of 2019
H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019
H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
H.R. 6201, Families First Coronavirus Response Act
H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act
H.R. 7617, Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021
S. 12, Health Savings Act of 2019
S. 61, Safe and Affordable Drugs from Canada Act of 2019
S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019
S. 64, Preserve Access to Affordable Generics and Biosimilars Act
S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act
S. 178, UIGHUR Act of 2019, including provisions relating to substitute amendment regarding COVID-19 relief package
S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019
S. 344, Hatch-Waxman Integrity Act of 2019
S. 470, Medicare at 50 Act
S. 684, Middle Class Health Benefits Tax Repeal Act of 2019
S. 692, Protect Medical Innovation Act of 2019
S. 1416, Affordable Prescriptions for Patients Act of 2019
S. 1541, Tobacco-Free Youth Act
S. 1895, Lower Health Care Costs Act
S. 2543, Prescription Drug Pricing Reduction Act of 2019
S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act
S. 3200, Chronic Disease Management Act of 2020
S. 4317, Safeguarding Americas Frontline Employees To Offer Work Opportunities Required to Kickstart the Economy (SAFE TO WORK) Act
Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.)
Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and
payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019)
Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Fed, Reg. 16,834, April 23, 2019)
Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020)
Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557;
Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs;
association health plans;
importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations;
balance or surprise billing and related issues;
single-payer health care options;
health reimbursement arrangements and other account-based group health plans;
Health and Human Services international pricing index (IPI) model;
legislation addressing mental health parity;
inclusion of prescription drug pricing on 2019 congressional agenda;
reauthorization of the Patient Centered Outcomes Research Institute; (PCORI);
potential premium reduction/reinsurance program to reduce health insurance premiums;
proposals to expand Medicare including Medicare Buy-In and the development of a public option;
medical hospital outpatient prospective payment system for CY 2020;
drug pricing including most-favored nations proposals, international pricing index, importation and mandatory rebates;
potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty;
comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements;
comments on Medicare Program; modernizing and clarifying the physician self-referral regulations;
comments on CMS proposed Medicaid fiscal accountability regulation;
comments on CMS proposed transparency in coverage rule;
comments to the U.S. Department of Health and Human Services on the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19, as amended on April 10, 2020 and June 8, 2020 (Declaration), Section 319F-3 of the Public Health Service (PHS) Act (42 U.S.C. 247d-6d);
comments to the U.S. Department of Health and Human Services on CMS-2393-P: Medicaid Program;
Medicaid fiscal accountability regulation;
comments to the U.S. Department of Health and Human Services on the Administrations proposed rule to eliminate drug manufacturer rebates in Part D;
transparency in coverage;
issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies;
Public Health and Social Services Emergency Fund (PHSSEF);
health insurance coverage during the coronavirus pandemic;
health legislative priorities for the potential Phase 4 coronavirus relief package;
provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements
(FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136);
FCCs COVID-19 Telehealth Program;
Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and
Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use;
reform of the World Health Organization (WHO);
continued U.S. membership in the World Health Organization
Public Readiness and Emergency Preparedness Act (P.L. 109-148, Division C), and COVID -19;
potential legislation dealing with COVID-19 liability issues
Client expense: $20,000,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Reclamation, Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Motor Carrier Safety Administration, Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation Security Administration (TSA), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR), White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Cited source text, amounts, lobbyists, and targets
H.R. 2207/S.692 - Protect Medical Innovation Act of 2019
no specific bill, tariff and trade policies
H.R. 1865 - Further Consolidated Appropriations Act, 2020
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Cited source text, amounts, lobbyists, and targets
S.692 & H.R.2207 - Protect Medical Innovation Act of 2019
S.503 & H.R.1366 - Responsible Additions & Increases to Sustain Employee Health Benefits Act of 2019
S.684 - Middle Class Health Benefits Tax Repeal Act of 2019
Client expense: Not reported · Firm income: $20,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Occupational Safety & Health Administration (OSHA), SENATE, Treasury, Dept of
Cited source text, amounts, lobbyists, and targets
H.R. 3, Lower Drug Costs Now Act of 2019
H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019
H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019
H.R. 448/S. 99, Medicare Drug Price Negotiation Act
H.R. 748/ S. 3548, Coronavirus Aid, Relief, and Economic Security (CARES) Act
H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019
H.R. 1384, Medicare for All Act of 2019
H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019
H.R. 1425, Patient Protection and Affordable Care Enhancement Act
H.R. 1865, Further Consolidated Appropriations Act, 2020
H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019
H.R. 1985, Family Savings for Kids and Seniors Act
H.R. 2207, Protect Medical Innovation Act of 2019
H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019
H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
H.R. 6201, Families First Coronavirus Response Act
H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act
S. 12, Health Savings Act of 2019
S. 61, Safe and Affordable Drugs from Canada Act of 2019
S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019
S. 64, Preserve Access to Affordable Generics and Biosimilars Act
S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act
S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019
S. 344, Hatch-Waxman Integrity Act of 2019
S. 470, Medicare at 50 Act
S. 684, Middle Class Health Benefits Tax Repeal Act of 2019
S. 692, Protect Medical Innovation Act of 2019
S. 1416, Affordable Prescriptions for Patients Act of 2019
S. 1541, Tobacco-Free Youth Act
S. 1895, Lower Health Care Costs Act
S. 2543, Prescription Drug Pricing Reduction Act of 2019
S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act
S. 3200, Chronic Disease Management Act of 2020
Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.)
Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and
payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019)
Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Federal Register 16,834, April 23, 2019)
Proposed regulations on Medicare modernizing and clarifying physician self-referral regulations (84 Fed. Reg. 55,766-55,847, October 17, 2019)
Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020)
Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557;
Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs;
association health plans;
importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations;
balance or surprise billing and related issues;
single-payer health care options;
health reimbursement arrangements and other account-based group health plans;
Health and Human Services international pricing index (IPI) model;
legislation addressing mental health parity;
inclusion of prescription drug pricing on 2019 congressional agenda;
reauthorization of the Patient Centered Outcomes Research Institute; (PCORI);
potential premium reduction/reinsurance program to reduce health insurance premiums;
medical hospital outpatient prospective payment system for CY 2020;
drug pricing;
potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty;
comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements;
comments on Medicare Program; modernizing and clarifying the physician self-referral regulations;
comments on CMS proposed Medicaid fiscal accountability regulation;
comments on CMS proposed transparency in coverage rule;
comments on HHS notice of benefit and payment parameters for 2021;
transparency in coverage;
Medicaid fiscal accountability regulations;
issues relating to the coronavirus pandemic, including testing, liability protection, and temporary COBRA subsidies;
Public Health and Social Services Emergency Fund (PHSSEF);
health insurance coverage during the coronavirus pandemic;
health legislative priorities for the potential Phase 4 coronavirus relief package;
provisions relating to Health Savings Accounts (HSA) and Flexible Spending Arrangements
(FSA) in the Coronavirus, Aid, Relief, and Economic Security (CARES) Act (P.L. 116-136);
FCCs COVID-19 Telehealth Program;
Federal Emergency Management Agencys (FEMA) temporary rule regarding Prioritization and
Allocation of Certain Scarce or Threatened Health and Medical Resources for Domestic Use
Client expense: $12,300,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Labor Statistics (BLS), Bureau of Reclamation, Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Motor Carrier Safety Administration, Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation Security Administration (TSA), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR), White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Cited source text, amounts, lobbyists, and targets
H.R. 2207/S.692 - Protect Medical Innovation Act of 2019
no specific bill, tariff and trade policies
H.R. 1865 - Further Consolidated Appropriations Act, 2020
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Disease Control & Prevention (CDC), Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, Small Business Administration (SBA), Treasury, Dept of, White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Cited source text, amounts, lobbyists, and targets
S.692 & H.R.2207 - Protect Medical Innovation Act of 2019
S.503 & H.R.1366 - Responsible Additions & Increases to Sustain Employee Health Benefits Act of 2019
S.684 - Middle Class Health Benefits Tax Repeal Act of 2019
Client expense: Not reported · Firm income: $20,000
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), SENATE, Treasury, Dept of
Cited source text, amounts, lobbyists, and targets
H.R. 3, Lower Drug Costs Now Act of 2019
H.R. 19/S. 3129, Lower Costs, More Cures Act of 2019
H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019
H.R. 448/S. 99, Medicare Drug Price Negotiation Act
H.R. 748, Coronavirus Aid, Relief, and Economic Security (CARES) Act
H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019
H.R. 1384, Medicare for All Act of 2019
H.R. 1398/S. 172, Health Insurance Tax Relief Act of 2019
H.R. 1865, Further Consolidated Appropriations Act, 2020
H.R. 1922/S. 1089, Restoring Access to Medication Act of 2019
H.R. 1985, Family Savings for Kids and Seniors Act
H.R. 2207, Protect Medical Innovation Act of 2019
H.R. 3030, Patient-Centered Outcomes Research Extension Act of 2019
H.R. 6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
H.R. 6201, Families First Coronavirus Response Act
S. 12, Health Savings Act of 2019
S. 61, Safe and Affordable Drugs from Canada Act of 2019
S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019
S. 64, Preserve Access to Affordable Generics and Biosimilars Act
S. 80, Jobs and Premium Protection Act, including provisions relating to repeal of the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act
S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019
S. 344, Hatch-Waxman Integrity Act of 2019
S. 470, Medicare at 50 Act
S. 684, Middle Class Health Benefits Tax Repeal Act of 2019
S. 692, Protect Medical Innovation Act of 2019
S. 1416, Affordable Prescriptions for Patients Act of 2019
S. 1541, Tobacco-Free Youth Act
S. 1895, Lower Health Care Costs Act
S. 1948, Chronic Disease Management Act of 2019
S. 2543, Prescription Drug Pricing Reduction Act of 2019
S. 2897, Patient-Centered Outcomes Research Institute Reauthorization Act
S. 3200, Chronic Disease Management Act of 2020
S. 3548, Coronavirus Aid, Relief, and Economic Security Act or the CARES Act
Potential legislation similar to H.R. 2911/S. 1697, Small Business Healthcare Relief Act (114th Cong.)
Proposed regulation on the Patient Protection and Affordable Care Act; HHS notice of benefit and
payment parameters for 2020 (84 Fed. Reg. 227-321, January 24, 2019)
Proposed regulations on Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; interoperability and patient access for Medicare advantage organization and Medicaid managed care plans, state Medicaid agencies, CHIP agencies and CHIP managed care entities, issuers of qualified health plans in the federally-facilitated exchanges and health care providers; supplement and extension of comment period (84 Federal Register 16,834, April 23, 2019)
Proposed regulations on transparency in health insurance coverage (84 Fed. Reg. 65,464-65,523, November 27, 2019)
Proposed regulations on Medicare modernizing and clarifying physician self-referral regulations (84 Fed. Reg. 55,766-55,847, October 17, 2019)
Proposed regulation on Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2021; notice requirement for non-federal governmental plans (85 Fed. Reg. 7,088-7,159, February 6, 2020)
Proposed regulation on Medicare and Medicaid Programs; Contract Year 2021 and 2022 Policy and technical changes to the Medicare Advantage Program, Medicare prescription drug benefit program, Medicaid program, Medicare cost plan program, and programs of all-inclusive care for the elderly (85 Fed. Reg. 9,002-9,260, February 18, 2020)
Various issues relating to Patient Protection and Affordable Care Act (P.L. 111-148) and the Health Care and Education Affordability Reconciliation Act of 2010 (P.L. 111-152), including the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, delivery system reform, health savings account (HSAs), health reimbursement account (HRAs), and flexible spending account (FSAs) changes, IPAB, employer mandate, reporting requirements for issuers and applicable large employers, premium stabilization programs, medical loss ratio, medical malpractice reform, exchanges, the impact on small business, the Small Business Tax Credit, section 1332 waivers, section 1557 on nondiscrimination, caps on compensation deductibility required under section 9014, incompleteness or inaccuracy of cost impact analysis, lack of quantified benefit analysis, and need for empirical data sources on which to base costs and benefits, the Cost Sharing Reduction (CSR) program, the section 9010 Health Insurance Providers Fee or Health Insurance Tax (HIT), 40% excise tax on high-cost employer-sponsored health coverage (Cadillac tax); medical device tax; protect Medicare Part Ds Non-Interference Clause from repeal, proposed rule regarding section 1557;
Public Health Services Act (P.L.78-410), Internal Revenue Code and the Employee Retirement Income Security Act (ERISA) (P.L. 93-406), regarding regulatory process and legislative corrections to ERISA preemption, changes to Medicare Advantage and Parts B, C, and D, including rebates and non-interference with prescription drug prices, entitlement reform, health information technology, telemedicine services in Medicare, and coordination and disease management programs;
association health plans;
importation of foreign pharmaceuticals into the United States and preemptive authority of federal food and drug regulations;
balance or surprise billing and related issues;
single-payer health care options;
health reimbursement arrangements and other account-based group health plans;
Health and Human Services international pricing index (IPI) model;
legislation addressing mental health parity;
inclusion of prescription drug pricing on 2019 congressional agenda;
reauthorization of the Patient Centered Outcomes Research Institute;
potential premium reduction/reinsurance program to reduce health insurance premiums;
medical hospital outpatient prospective payment system for CY 2020;
drug pricing;
potential healthcare pricing proposals, including a medicaid rebate cap, spread pricing, and inflation penalty;
comments on Medicare and State Healthcare Programs: fraud and abuse; revisions to safe harbors under the anti-kickback statute, and civil monetary penalty rules regarding beneficiary inducements;
comments on Medicare Program; modernizing and clarifying the physician self-referral regulations;
comments on CMS proposed Medicaid fiscal accountability regulation;
comments on CMS proposed transparency in coverage rule;
comments on HHS notice of benefit and payment parameters for 2021;
Medicaid fiscal accountability regulations;
transparency on coverage;
issues relating to the coronavirus pandemic
Client expense: $15,770,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Army, Dept of (Corps of Engineers), Bureau of Citizenship & Immigration Services (BCIS), Bureau of Industry and Security (BIS), Bureau of Labor Statistics (BLS), Bureau of Reclamation, Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Financial Protection Bureau (CFPB), Council of Economic Advisers (CEA), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Equal Employment Opportunity Commission (EEOC), Executive Office of the President (EOP), Federal Aviation Administration (FAA), Federal Communications Commission (FCC), Federal Deposit Insurance Corporation (FDIC), Federal Emergency Management Agency (FEMA), Federal Energy Regulatory Commission (FERC), Federal Motor Carrier Safety Administration, Federal Reserve System, Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Institute of Standards & Technology (NIST), Natl Labor Relations Board (NLRB), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Office of the Comptroller of the Currency (OCC), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), Small Business Administration (SBA), State, Dept of (DOS), Transportation Security Administration (TSA), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR), White House Office
Cited source text, amounts, lobbyists, and targets
Implementation of PL 114-255, 21st Century Cures Act
Implementation of PL-111-148, PPACA
Ensuring Patient Access to Critical Breakthrough Products
Policies promoting medical innovation
Heart Valve Disease Awareness
Implementation of PL-115-201, FDA Reauthorization Act of 2017
H.R. 2207 Protect Medical Innovation (Device Tax Repeal)
S. 692 (Medical Device Tax Repeal)
Implementation of PL 114-10, MACRA
Cybersecurity for Healthcare Industry
FDA Reauthorization for 2022/FDA User Fees
H.R. 6074/S. 3548 Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
Client expense: $340,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
Government targets: Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Natl Institutes of Health (NIH), SENATE, White House Office
Cited source text, amounts, lobbyists, and targets
Issues related to the repeal of the medical device excise tax, including S.692 and H. R. 2207, the Protect Medical Innovation Act of 2019, and H. R. 1865, the Further Consolidated Appropriations Act of 2020.
Client expense: Not reported · Firm income: $80,000
Cited source text, amounts, lobbyists, and targets
Issues related to medical device excise tax (Protect Medical Innovation Act, S. 692/H.R. 2207); flexible spending account limits and treasury rulings on rollovers; RAISE Act (H.R. 1366/S. 503); tax policy proposals and implementation of comprehensive tax reform, including small business tax issues, pass-throughs, student loan interest deduction, higher education tax credits and benefits, dental faculty loan repayment assistance (H.R. 996/S. 359), ACA tax implementation; and student loan debt on medical professional small business owners. Middle Class Health Benefits Tax Repeal Act of 2019 (H.R. 748). Policy issues related to tax, small business and the federal response to the COVID-19 virus.
Client expense: Not reported · Firm income: $50,000
Cited source text, amounts, lobbyists, and targets
Issues related to medical device tax repeal (Protect Medical Innovation Act, H.R. 2207/S. 692) and expanded use of flexible spending accounts, health savings accounts, and association health plans (H.R. 2294/S. 1170), market stabilization efforts, issues related to oral health care, and health care workforce issues. Responsible Additions and Increases to Sustain Employee Health Benefits Act of 2019 (H.R. 1366/S. 503). Legislation to repeal Affordable Care Act limits on flexible spending accounts. Issues related to small business health care providers, including the Small Business Health Account Act. Ensuring Lasting Smiles Act (H.R. 1379/S. 560). FY 2021 Labor-HHS-Education appropriations; Policy issues related to health care and the federal response to the COVID-19 virus.
Client expense: Not reported · Firm income: $50,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Cited source text, amounts, lobbyists, and targets
Legislative and regulatory services related to tax reform, PL 115-97 Tax Cuts and Jobs Act and S.692, Protect Medical Innovation Act of 2019, H.R. 2207, Protect Medical Innovation Act of 2019, and H.R. 748, Coronavirus Aid, Relief, and Economic Security (CARES) Act.
Client expense: Not reported · Firm income: $60,000
Cited source text, amounts, lobbyists, and targets
H.R. 2207/S.692 - Protect Medical Innovation Act of 2019
no specific bill, tariff and trade policies
H.R. 1865 - Further Consolidated Appropriations Act, 2020
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Cited source text, amounts, lobbyists, and targets
Support for S. 692 - Protection Medical Innovation Act of 2019. Support for H.R. 2207 - To amend the Internal Revenue Code of 1986 to repeal the excise tax on medical devices.
Client expense: Not reported · Firm income: $30,000
Cited source text, amounts, lobbyists, and targets
Medical device tax; tax issues; Implementation of the Tax Cuts and Jobs Act (P.L. 115-97); Repeal of medical device tax; H.R. 2207, S. 692 Protecting Medical Innovation Act of 2019.
Client expense: Not reported · Firm income: $20,000
Government targets: Commerce, Dept of (DOC), Energy, Dept of, Environmental Protection Agency (EPA), Federal Highway Administration (FHA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Patent & Trademark Office (PTO), Pipeline & Hazardous Materials Safety Administration, SENATE, Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Government targets: Commerce, Dept of (DOC), Energy, Dept of, Environmental Protection Agency (EPA), Federal Highway Administration (FHA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Patent & Trademark Office (PTO), Pipeline & Hazardous Materials Safety Administration, SENATE, Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
Cited source text, amounts, lobbyists, and targets
H.R. 3301, Taxpayer Certainty and Disaster Tax Relief Act of 2019, Sec. 145. Look-thru rule for related controlled foreign corporations. H.R. 2207/S.692, Protect Medical Innovation Act of 2019 (Repeal of medical device tax) all sections.
Client expense: $220,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
S.692 & H.R.2207 - Protect Medical Innovation Act of 2019
S.503 & H.R.1366 - Responsible Additions & Increases to Sustain Employee Health Benefits Act of 2019
S.684 & H.R.748 - Middle Class Health Benefits Tax Repeal Act of 2019
Client expense: Not reported · Firm income: $20,000
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), SENATE
Cited source text, amounts, lobbyists, and targets
Support proposals to repeal the Medical Device Tax, including S. 692 / H.R. 2207, the Protect Medical Innovation Act of 2019, and H.R. 1865, the Further Consolidated Appropriations Act, 2020.
Client expense: Not reported · Firm income: $80,000
Cited source text, amounts, lobbyists, and targets
S. 692, Protect Medical Innovation Act, to repeal the excise tax on medical devices
H.R.1865, the Further Consolidated Appropriations Act, 2020, repeal medical device excise tax, repeal ACA Cadillac tax
H.R. 2207, the Protect Medical Innovation Act of 2019, to amend the Internal Revenue Code of 1986 to repeal the excise tax on medical devices
Client expense: $30,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
S. 692, Protect Medical Innovation Act, to repeal the excise tax on medical devices
H.R.1865, the Further Consolidated Appropriations Act, 2020, repeal medical device excise tax, repeal ACA Cadillac tax
H.R. 2207, the Protect Medical Innovation Act of 2019, to amend the Internal Revenue Code of 1986 to repeal the excise tax on medical devices
Client expense: $30,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
Medical device excise tax
H.R.2207 and S.692 (Protect Medical Innovation Act of 2019), all provisions
H.R. 1865 (Further Consolidated Appropriations Act, 2020), Division N, Title I, Section 501, regarding medical device excise tax
Client expense: Not reported · Firm income: $10,000
Cited source text, amounts, lobbyists, and targets
H.R. 2207, S. 692, and related bills related to repeal of the medical device excise tax
Issues related to the reform of the tax code and tax credits for investors in pre-revenue and start-up medical technology companies.
Client expense: $1,750,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
S.617, Tax extender and Disaster Relief Act - bill in its entirety; H.R.2207, Repeal the Excise Tax on Medical Devices; Public Law 115-9 (Tax Cuts and Jobs Act) - issues surrounding the Base Erosion Anti Abuse Tax (BEAT); Section 245A and the future of Section 385 regulations; global digital tax proposals; H.R.2207 and S.692, Protect Medical Innovation Act of 2019 - To amend the Internal Revenue Code of 1986 to repeal the excise tax on medical device issues related to medical device tax; S.1094 and H.R.2256, Driving America Forward Act; S.1142 and H.R.2096, Energy Storage Tax Incentive and Deployment Act of 2019; Section 48 - issues related to energy; Section 45 - issues related to energy; H.R.2207 & S.692, Protect Medical Innovation Act of 201 - repeal medical device excise tax and S.1988, Incentivizing Offshore Wind Power Act; S.1957, Offshore WIND Act.
Client expense: $870,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Energy, Dept of, Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Interior, Dept of (DOI), Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE, Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR)
Cited source text, amounts, lobbyists, and targets
Issues related to medical device tax;
Protect Medical Innovation Act of 2019 (S.692/H.R.2207);
Further Consolidated Appropriations Act, 2020 (H.R. 1865).
Client expense: Not reported · Firm income: $50,000
Cited source text, amounts, lobbyists, and targets
Monitor issues as they relate to the implementation of tax reform. Repeal of the Medical Device Tax (S.692 / H.R. 1865/ H.R. 2207, Protect Medical Innovation Act of 2019).
Client expense: Not reported · Firm income: $80,000
Government targets: Commerce, Dept of (DOC), Energy, Dept of, Environmental Protection Agency (EPA), Federal Highway Administration (FHA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Highway Traffic Safety Administration (NHTSA), Patent & Trademark Office (PTO), Pipeline & Hazardous Materials Safety Administration, SENATE, Transportation, Dept of (DOT), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office